3-(3,4-Dihydro-2H-pyrrol-5-yl)pyridine; 3-(1-Pyrrolin-2-yl)pyridine; Miosmine; UNII-9O0A545W4L; 3-(4,5-Dihydro-3H-pyrrol-2-yl)-pyridine; MFCD00052019; Pyridine, 3-(3,4-dihydro-2H-pyrrol-5-yl)-; 3-(1-PYRROLIN-2-YL)-PYRIDINE; 2-(3-Pyridyl)-1-pyrroline; CHEMBL423429; 3-(2-Pyrrolin-2-yl)pyridine; 9O0A545W4L; Pyridine, 3-(1-pyrrolin-2-yl)-; CCRIS 9356; Prestwick_202; Myosmine, 98%; Spectrum_001130; Nicotine EP Impurity D; SpecPlus_000615; Prestwick0_000647; Prestwick1_000647; Prestwick2_000647; Prestwick3_000647; Nicotine Related Compound D; BSPBio_000653; KBioSS_001610; 5-23-06-00466 (Beilstein Handbook Reference); DivK1c_006711; SPBio_002574; BPBio1_000719; SCHEMBL5319476; KBio1_001655; KBio2_001610; KBio2_004178; KBio2_006746; DTXSID70891866; US8609708, 79 Myosmine; HMS1570A15; HMS2097A15; ZINC159590; KS-000002EY; 5048AE; BBL100560; BDBM50125053; s3311; STL554354; 3-(1-Pyrrolin-2-yl)pyridine, 8CI; AKOS005254654; CCG-214475; CS-W001909; HY-W001909; MCULE-7478723183; NCGC00016493-01; NCGC00016493-02; NCGC00163359-01; MS-20037; 1-AMINO-CYCLOPENT-3-ENECARBOXYLICACID; 3-(3,4-Dihydro-2H-pyrrol-5-yl)-Pyridine; FT-0629049; FT-0672571; ST50824026; 3-(3,4-Dihydro-2H-pyrrol-5-yl)pyridine #; C10160; X-4253; 3-(3,4-Dihydro-2H-pyrrol-5-yl)pyridine, 9CI; Q411486; 3-(4,5-Dihydro-3H-pyrrol-2-yl)pyridine (Myosmine); BRD-K67556876-001-03-1; BRD-K67556876-001-04-9; Pyridine, 3-(3,4-dihydro-2H-pyrrol-5-yl)- (9CI)